About inavolisib
PI3K-alpha inhibitor
Used for
- With fulvestrant for adults with hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer after prior endocrine therapy.
Usual adult dose
9 mg by mouth once daily with food for 21 days, then 7 days off, in 28-day cycles; used with fulvestrant.
Common side effects
- High blood sugar
- Diarrhea
- Rash
- Mouth sores
Important warnings
- Can cause severe or life-threatening high blood sugar; monitor blood glucose.
- Severe diarrhea, skin reactions, and lung inflammation can occur.
- Check for PIK3CA mutations before treatment.
- Avoid strong CYP3A inhibitors and inducers; review all medicines.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for one week afterward.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong CYP3A inhibitors may increase drug levels.
- Strong CYP3A inducers may reduce effectiveness.
- May reduce effectiveness of hormonal contraceptives; use non-hormonal contraception.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.